Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca appoints Sean Bohen as chief medical officer

Dr Bohen will join the firm from Genentech

AstraZeneca Sean BohenAstraZeneca has appointed Dr Sean Bohen as chief medical officer and executive vice president of global medicines development starting 15 September.

Bohen joins from Genentech where he was senior vice president of early development.

At Genentech, he managed preclinical and clinical development programmes across all therapy areas and prior to this position was also a key figure in the growth and progress of the Genentech-Roche portfolio.

As CMO he will ensure patient safety across AZ's entire portfolio and additionally be responsible for pushing medicines from late-stage development through to regulatory approval.

Pascal Soriot, CEO at AZ, said: “I'm delighted to welcome Sean to AstraZeneca at a very exciting time for our company.

“Sean is a tremendous scientist and accomplished drug developer. His impressive expertise in key areas of our exciting pipeline, including oncology and immunology, will further strengthen and accelerate the delivery of new medicines for patients.

“His extensive diagnostics experience will also reinforce our efforts in precision medicine.”

Before joining Genentech he was a clinical instructor in oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the National Cancer Institute.

AZ's former CMO, Briggs Morrisson, surprised many when he left earlier in June to join a privately owned US biotech company.

25th August 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...

Infographics